著者: Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close, Claudio Cobelli, Eyal Dassau, J Hans DeVries, Kim C Donaghue, Klemen Dovc, Francis J Doyle, Satish Garg, George Grunberger, Simon Heller, Lutz Heinemann, Irl B Hirsch, Roman Hovorka, Weiping Jia, Olga Kordonouri, Boris Kovatchev, Aaron Kowalski, Lori Laffel, Brian Levine, Alexander Mayorov, Chantal Mathieu, Helen R Murphy, Revital Nimri, Kirsten Nørgaard, Christopher G Parkin, Eric Renard, David Rodbard, Banshi Saboo, Desmond Schatz, Keaton Stoner, Tatsuiko Urakami, Stuart A Weinzimer, Moshe Phillip
雑誌名: Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8.
Abstract/Text: Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
© 2019 by the American Diabetes Association.
Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub...
